|
Daniel M. Bradbury has been Chief Executive Officer of Amylin Pharmaceuticals, Inc. since March 2007, serving as President and Chief Operating Officer since 2003. He has served as a director of Amylin since June 2006. He joined Amylin in 1994 and has held officer-level positions in Corporate Development and Marketing during that time. Prior to joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham Pharmaceuticals, where he held a number of sales and marketing positions. He is a member of the board of directors of Cerexa, Inc., Illumina, Inc. and Novacea, Inc. He also serves as a board member for BIOCOM. Mr. Bradbury is a member of the Royal Pharmaceutical Society of Great Britain and serves as Chair of the Advisory Council of the Keck Graduate Institute. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education. | 